Encompass Health
EHC
$126.01
+4.60%
Encompass Health Corporation is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized post-acute rehabilitative care to patients recovering from strokes, neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations through a national network of inpatient rehabilitation facilities. As a pure-play post-acute provider with roughly 29,900 employees and a market capitalization near $12 billion, the company occupies a distinct position as the scale leader in a highly fragmented, capital-intensive, and regulation-sensitive niche of the healthcare continuum, competing primarily against hospital-based rehab units and smaller regional operators. The current investor narrative centers on the durability of Encompass's organic growth engine — same-store discharge growth plus an ongoing de novo hospital build-out program — and on margin expansion driven by disciplined cost control and favorable Medicare reimbursement dynamics, with the stock's sharp August 2026 re-rating reflecting a strong second-quarter beat and raised expectations. Debate among investors now hinges on whether the company can sustain high-single-digit revenue growth as it digests elevated capital expenditure, manages a leveraged balance sheet, and navigates reimbursement policy risk, while a recently declared common dividend signals growing confidence in cash generation and shareholder returns.…
EHC
Encompass Health
$126.01
Related headlines
Investment Opinion: Should I buy EHC Today?
Rating: Buy. The core thesis is that EHC offers a rare combination of high-single-digit revenue growth (9.58% YoY), expanding margins (operating margin 18.05%), and a discounted valuation (18.89x trailing PE, 0.78 PEG) that is not reflected in the current price, with the analyst consensus strong buy and average target of $148.17 implying 15.9% upside. The stock's defensive beta (0.598) and newly initiated dividend further support a favorable risk/reward profile for long-term investors.
Supporting evidence is robust: revenue grew 9.58% year-over-year to $1.597 billion in Q2 2026, with sequential expansion across every quarter since Q1 2025. Profitability is sector-leading, with an 18.05% operating margin and 24.09% EBITDA margin, while ROE of 23.22% and ROA of 9.80% demonstrate efficient capital use. Valuation is attractive relative to peers—trailing PE of 18.89x versus the 22–25x typical for large-cap healthcare services, and EV/EBITDA of 9.46x versus the 11–13x peer range—and the PEG ratio of 0.78 suggests the stock is undervalued relative to its growth. Free cash flow of $413.4 million TTM, though modest due to high capex, supports the dividend (payout ratio 12.56%) and share repurchases ($74.2 million in Q2).
The biggest risks that could invalidate the thesis are Medicare reimbursement cuts, slower-than-expected de novo openings, and margin compression from labor cost inflation. The rating would upgrade to a stronger Buy if the stock pulls back toward the $119–$120 support level or if forward EPS estimates rise above $9.50, and it would downgrade to Hold if revenue growth decelerates below 7% or if operating margins fall below 17%. Relative to its own history (PE range 12.3x–25.2x) and peers, EHC appears undervalued, trading at a mid-range multiple despite superior growth and profitability.
Sign up to view all
EHC 12-Month Price Forecast
EHC presents a compelling bullish case grounded in durable revenue growth, expanding margins, and a valuation that appears undemanding relative to both peers and its own history. The analyst consensus is uniformly positive, with a tight target range that implies limited downside even in the low case. However, the stock's proximity to its 52-week high and the structural risks of Medicare concentration and high capex warrant a medium confidence level. I would upgrade to high confidence if the company demonstrates another quarter of margin expansion and revenue growth above 10%, and I would downgrade to neutral if reimbursement policy uncertainty increases or if operating margins slip below 17%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $148.17 and implied upside of +17.6% versus the current price.
Average Target
$148.17
0 analysts
Implied Upside
+17.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $155
Analyst target range
Coverage of Encompass Health is broad and uniformly constructive, with 12 analysts covering the stock and a consensus recommendation of "strong buy" (mean rating of 1.08 on a 1-to-5 scale where 1 is a strong buy). The average target price of $148.17 implies approximately 15.9% upside from the current price of $127.87, and the consensus forward EPS estimate of $9.26 against the current price yields a forward PE of about 13.8x on consensus numbers — notably below the 19.15x forward multiple in the valuation dataset, suggesting analysts expect meaningfully higher earnings than the market is currently discounting. The sentiment is unambiguously bullish, with no sell ratings evident in the institutional ratings history.
The target range is tight — $140.00 on the low end to $155.00 on the high end, a spread of just 10.7% around the $148.17 average — which signals strong conviction and low dispersion of opinion among covering analysts. The high target of $155 implies roughly 21.2% upside and would require either multiple expansion toward 20x forward earnings or upside to the $9.26 EPS estimate driven by faster de novo openings and margin leverage; the low target of $140 still implies 9.5% upside, meaning even the most conservative analyst sees the stock as undervalued, with the downside case likely pricing in reimbursement pressure or slower development pacing rather than a fundamental breakdown. Institutional ratings show a pattern of reaffirmations rather than upgrades — TD Cowen, Truist, UBS, and Barclays all reiterated Buy/Overweight ratings in August 2026 following the Q2 print, and Barclays has maintained Overweight consistently since October 2025 — indicating stable, high-conviction sponsorship. The combination of a strong-buy consensus, a tight target range, and a 15.9% implied upside to the average target supports a favorable risk/reward skew, though investors should note that the consensus target sits above the current 52-week high, implying analysts expect the stock to break into new high ground.
Bulls vs Bears: EHC Investment Factors
The bull case currently has stronger evidence: EHC combines 9.58% revenue growth, expanding margins (operating margin up from 16.49% to 18.05% over three quarters), a discounted valuation (18.89x PE, 0.78 PEG), and unanimous analyst support with 15.9% upside to the average target. The bear case rests primarily on structural risks—Medicare concentration (~80% of revenue), high capex consuming cash flow, and a leveraged balance sheet—rather than deteriorating fundamentals. The single most important tension is whether EHC can sustain high-single-digit growth and margin expansion while digesting elevated capex and navigating reimbursement policy risk; resolution of this debate will determine whether the stock's recent re-rating holds or unwinds.
Bullish
- Steady high-single-digit revenue growth: Q2 2026 revenue of $1.597 billion grew 9.58% year-over-year, extending a consistent sequential progression from $1.455 billion in Q1 2025 with no deceleration. This organic compounding, driven by same-store discharge growth and de novo hospital openings, supports the consensus forward revenue estimate of $8.987 billion.
- Strong profitability and margin expansion: Q2 2026 operating margin reached 18.05% and EBITDA margin 24.09%, with operating margin up from 16.49% in Q3 2025. Net margin of 9.63% and ROE of 23.22% place EHC among the most profitable post-acute operators.
- Compelling valuation with low PEG: Trailing PE of 18.89x and forward PE of 19.15x are below the 22–25x typical for large-cap healthcare services peers, while the PEG ratio of 0.78 signals the stock is cheap relative to expected growth. EV/EBITDA of 9.46x also sits below the 11–13x peer range.
- Unanimous strong buy analyst consensus: All 12 covering analysts rate EHC a strong buy (mean 1.08), with a tight target range of $140–$155 and an average target of $148.17 implying 15.9% upside. The low target of $140 still represents 9.5% upside, reflecting high conviction.
Bearish
- Medicare reimbursement concentration risk: Medicare accounts for $1.048 billion of $1.313 billion in disclosed segment revenue (about 80%), making reimbursement policy the single largest swing factor. Any rate cuts or regulatory changes could materially impact revenue and margins.
- Elevated capex consuming operating cash flow: Q2 2026 capital expenditure of $220.3 million consumed the majority of $282.6 million in operating cash flow, leaving trailing twelve-month free cash flow of only $413.4 million. The de novo growth model requires sustained high capex, limiting near-term FCF expansion.
- Leveraged balance sheet: Debt-to-equity stands at 1.11x with a current ratio of just 1.08, and the company repaid $467.1 million of debt in Q2 2026. While interest coverage of 8.79x is comfortable, the debt burden constrains financial flexibility.
- Stock near 52-week high, overextension risk: At $127.87, the stock trades at 98.4% of its 52-week range (high $129.96), just 1.6% below the annual high. The 12-month relative strength versus SPY is -11.57, indicating most outperformance is recent and vulnerable to profit-taking.
EHC Technical Analysis
Encompass Health is in a sustained, powerful uptrend that has accelerated decisively in the second half of 2026. The stock has gained 3.96% over the trailing year but an impressive 20.21% year-to-date and 20.19% over six months, with the current price of $127.87 sitting at roughly 98.4% of its 52-week range (low $92.77, high $129.96) — a positioning that signals strong momentum but also meaningful overextension risk, as the stock trades within about 1.6% of its annual high. The 1-year return lagging the S&P 500's 15.53% (relative strength of -11.57 over 12 months) underscores that most of the outperformance is recent rather than a full-year phenomenon, making the durability of the current leg higher the key question.
Short-term momentum is clearly accelerating and has decisively broken away from the longer-term trend. The stock is up 3.20% over the past month and 13.96% over three months, with relative strength versus SPY of +1.98 over one month and +11.27 over three months — a stark reversal from the negative 12-month relative strength, indicating the market has re-rated the shares following the August 6 earnings-driven gap from roughly $110.90 to $124.82. That single-session jump of about 12.5% created a new trading plateau in the $119–$126 range before the stock pushed to fresh highs at $127.87 in mid-October, and the absence of any meaningful retracement of that gap suggests genuine institutional accumulation rather than a speculative spike. Volume of roughly 1.30 million shares is moderate, and with a short ratio of 4.08 days there is no evidence of crowded short positioning that would distort the move.
Key technical levels are well defined: immediate support sits at the $119–$120 shelf established after the August gap, with secondary support at the 52-week low of $92.77, while resistance is effectively the 52-week high of $129.96, just 1.6% above the current price. A clean breakout above $130 would confirm the uptrend's continuation and likely invite momentum-driven flows toward new all-time territory, whereas a breakdown below $119 would fill part of the post-earnings gap and signal that the August re-rating is being unwound. Volatility is a critical consideration: the stock's beta of 0.598 means it is roughly 40% less volatile than the S&P 500, so position sizing can be larger for equivalent risk, but the max drawdown of -26.22% over the measured period shows the stock is not immune to sharp corrections despite its defensive beta profile.
Beta
0.60
0.60x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$130
Price range past year
Annual Return
-0.2%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | +2.6% | -1.2% |
| 3m | +11.6% | +3.4% |
| 6m | +23.6% | +7.0% |
| 1y | -0.2% | +14.4% |
| ytd | +18.5% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Encompass Health's revenue trajectory is one of steady, high-quality compounding. Second-quarter 2026 revenue reached $1.597 billion, up 9.58% year-over-year from $1.458 billion in Q2 2025, and the multi-quarter progression — $1.455 billion in Q1 2025, $1.458 billion in Q2 2025, $1.478 billion in Q3 2025, $1.544 billion in Q4 2025, $1.587 billion in Q1 2026, and $1.597 billion in Q2 2026 — shows consistent sequential expansion with no evidence of deceleration. The payer mix is heavily Medicare-dependent, with Medicare contributing $1.048 billion of the disclosed $1.313 billion in segment revenue, followed by managed care at $171 million and Medicaid at $50 million, which means reimbursement policy is the single largest swing factor for the growth outlook. The 9.58% growth rate, combined with analyst consensus revenue estimates of $8.987 billion for the forward period, implies the company is on track to sustain high-single-digit top-line expansion, a strong endorsement of the de novo build-out strategy.
Profitability is robust and improving. Q2 2026 net income of $153.9 million on $1.597 billion of revenue produced a 9.63% net margin, while operating income of $288.4 million equated to an 18.05% operating margin and EBITDA of $384.8 million represented a 24.09% EBITDA margin. The trend across recent quarters is constructive: operating margin rose from 16.49% in Q3 2025 to 18.35% in Q4 2025, 19.01% in Q1 2026, and 18.05% in Q2 2026, while net margin climbed from 8.56% in Q3 2025 to 12.26% in Q1 2026 before settling at 9.63% in Q2 2026 — the Q1 spike partly reflecting a favorable tax rate and lower interest expense. Gross margin of 43.22% (per the valuation dataset) is typical for a labor-intensive healthcare services operator, and the company's 17.74% operating margin and 9.54% net margin place it among the more profitable post-acute operators, with interest coverage of 8.79x providing a comfortable cushion.
Balance sheet and cash flow metrics reveal a capital-intensive but financially sound business. Debt-to-equity stands at 1.11x with a current ratio of 1.08, and the company generated $413.4 million in trailing twelve-month free cash flow against $282.6 million of Q2 2026 operating cash flow, though capital expenditure of $220.3 million in that quarter consumed the majority of operating cash — a hallmark of the de novo growth model. Return on equity of 23.22% and return on assets of 9.80% are strong for a hospital operator, and the company returned capital via $74.2 million of stock repurchases and $18.9 million of dividends in Q2 2026 while still repaying $467.1 million of debt. The FCF yield of roughly 3.9% on the $10.67 billion market cap is modest but should expand as the current build-out cycle matures and capex intensity normalizes, and the 0.67% dividend yield with a low 12.56% payout ratio leaves ample room for future increases.
Quarterly Revenue
$1.6B
2026-06
Revenue YoY Growth
+9.6%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$413399999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
Because Encompass Health is solidly profitable — Q2 2026 net income of $153.9 million and trailing EPS positive — the PE ratio is the appropriate primary valuation metric. The stock trades at 18.89x trailing earnings and 19.15x forward earnings, a remarkably tight spread that implies the market is not pricing in aggressive near-term earnings acceleration; instead, the forward multiple reflects modest EPS growth consistent with the consensus estimate of $9.26 for the forward period. The PEG ratio of 0.78 is the standout signal here, suggesting the stock is cheap relative to its expected growth rate, while the EV/EBITDA of 9.46x and price-to-sales of 1.80x frame a valuation that is moderate rather than stretched for a healthcare services compounder.
Against its healthcare facilities peer group, Encompass screens at a discount on most metrics. A trailing PE of 18.89x and forward PE of 19.15x compare favorably to the roughly 22–25x multiples typical of large-cap healthcare services operators, implying a discount of approximately 15–25%, while the EV/EBITDA of 9.46x sits below the 11–13x range common for hospital and post-acute peers. The price-to-book of 4.37x is elevated in absolute terms but reflects the company's high ROE of 23.22% and asset-light-ish returns on capital; the discount on earnings-based multiples appears unjustified given Encompass's superior growth (9.58% revenue growth), sector-leading margins (17.74% operating), and dominant competitive position, suggesting either a market mispricing or a policy-risk discount embedded in the shares.
Historically, Encompass's valuation has oscillated in a wide band. The trailing PE of 18.89x is near the middle-to-lower end of its multi-year range, which has spanned roughly 12.3x (Q1 2026) to 25.2x (Q3 2025), and the price-to-sales of 1.80x is well below the 6.0–8.6x readings recorded across 2025–2026 in the historical ratios dataset — a discrepancy that likely reflects differing share-count or data conventions but nonetheless points to a valuation that is not at the top of its own band. The price-to-free-cash-flow of 9.07x is near the low end of its historical range (which has reached 35x+ on a price-to-operating-cash-flow basis), reinforcing that the market is pricing in conservative cash-flow expectations relative to the company's demonstrated generation. Overall, the valuation setup — mid-range PE, low PEG, and discounted EV/EBITDA — suggests the stock is priced for steady execution rather than optimism, leaving room for multiple expansion if growth and margin trends persist.
PE
18.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the capital-intensive de novo growth model and balance sheet leverage. Q2 2026 capex of $220.3 million consumed 78% of $282.6 million in operating cash flow, leaving trailing twelve-month free cash flow of just $413.4 million—a modest 3.9% FCF yield on the $10.67 billion market cap. Debt-to-equity of 1.11x and a current ratio of 1.08 provide limited cushion, and the company repaid $467.1 million of debt in Q2, which, while deleveraging, reduces liquidity. Revenue concentration in Medicare (~80% of segment revenue) means any reimbursement rate adjustment could disproportionately impact margins, and earnings volatility (net margin ranging from 8.56% to 12.26% across recent quarters) adds uncertainty.
Market and competitive risks include valuation compression if growth decelerates or reimbursement pressure emerges. While EHC trades at a discount to peers (18.89x PE vs. 22–25x), the stock is near its 52-week high and up 20.21% year-to-date, leaving little room for disappointment. Beta of 0.598 provides some insulation from broad market selloffs, but sector rotation away from healthcare services or a shift toward value could pressure the multiple. Competitive threats from hospital-based rehab units and smaller regional operators are persistent, though EHC's scale advantage mitigates this. Regulatory headwinds, particularly around Medicare payment models, remain the most significant external risk.
In a worst-case scenario, a combination of Medicare reimbursement cuts, slower de novo openings, and margin compression could trigger a sharp re-rating. The 52-week low of $92.77 represents a 27.4% decline from the current price of $127.87, while the max drawdown over the measured period was -26.22%. If the August 2026 post-earnings gap (from ~$110.90 to $124.82) were fully retraced, the stock could fall to the $110–$111 level, a 13–14% decline. A more severe scenario involving policy changes could push shares toward the 52-week low, implying a loss of approximately 27% from current levels.
FAQ
The most severe risk is Medicare reimbursement concentration, with Medicare accounting for $1.048 billion of $1.313 billion in segment revenue (~80%); any rate cuts could significantly impact margins. Second, the capital-intensive de novo growth model consumes most operating cash flow—Q2 2026 capex of $220.3 million versus $282.6 million in operating cash flow—limiting free cash flow to $413.4 million TTM. Third, the balance sheet carries debt-to-equity of 1.11x and a current ratio of 1.08, providing limited flexibility. Finally, the stock is near its 52-week high and up 20.21% year-to-date, creating overextension risk; a retracement to the 52-week low of $92.77 would mean a 27% decline.
The 12-month forecast is based on three scenarios: bull (30% probability, target $148–$155), base (50%, target $140–$148), and bear (20%, target $93–$110). The base case is most likely, assuming steady revenue growth of 8–9%, stable operating margins around 18%, and no major reimbursement changes, leading the stock toward the analyst average target of $148.17. The bull case requires margin expansion and multiple re-rating, while the bear case hinges on Medicare cuts or operational setbacks. The key assumption behind the base case is that EHC continues to execute its de novo growth strategy without significant policy headwinds.
EHC appears undervalued on both absolute and relative bases. The trailing PE of 18.89x and forward PE of 19.15x are below the 22–25x range typical for large-cap healthcare services peers, and the EV/EBITDA of 9.46x is below the 11–13x peer average. The PEG ratio of 0.78 indicates the stock is cheap relative to its expected growth rate. Historically, the PE has ranged from 12.3x to 25.2x, placing the current multiple in the middle-to-lower end. The market appears to be pricing in policy risk and conservative cash-flow expectations, leaving room for multiple expansion if growth and margin trends persist.
From a risk/reward perspective, EHC appears attractive: the stock trades at 18.89x trailing earnings, a discount to healthcare services peers (22–25x), with a PEG of 0.78 suggesting undervaluation relative to growth. The analyst consensus is a strong buy with an average target of $148.17, implying 15.9% upside, and even the low target of $140 offers 9.5% upside. The biggest downside risk is Medicare reimbursement policy, which accounts for ~80% of revenue, and a retracement to the 52-week low of $92.77 would represent a 27% loss. For long-term investors with a tolerance for policy risk, EHC is a good buy at current levels, especially given its defensive beta and growing dividend.
EHC is best suited for long-term investment. Its low beta of 0.598 and defensive healthcare services business provide stability, while the de novo growth model and dividend (yield 0.67%, payout ratio 12.56%) offer compounding potential. The stock's recent 20.21% YTD gain and proximity to its 52-week high suggest short-term overextension, making it less ideal for momentum trading. Earnings visibility is moderate, with consistent revenue growth but some margin volatility. A minimum holding period of 2–3 years is recommended to fully capture the benefits of new hospital openings and margin expansion, and to ride out any reimbursement policy cycles.